Navigation Links
Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Date:7/31/2012

inflammation.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. These forward-looking statements are based on Synergy's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the d
'/>"/>

SOURCE Synergy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... 2014 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... January 14, 2015, in San Francisco . ... Executive Officer, will speak at 11:00 AM Pacific Time.  A ... clicking on the Investor Relations link on the Cyberonics home ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
... Aug. 8, 2011 Symphony Corporation, a global ... of JGI, a New Jersey-based Human Capital Management ... in the healthcare industry nationally.  Symphony,s acquisition of ... to provide the highest level of benefits to ...
... 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... James P. Tursi has been promoted to Chief Medical ... Executive Officer and President of Auxilium, and sit on ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO) Dr. Tursi has been ...
Cached Medicine Technology:Symphony Corporation Acquires JGI to Provide End-to-End Services for Healthcare IT 2Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer 2Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer 3
(Date:12/25/2014)... December 26, 2014 The report “TS-1 ... focuses on the current treatment landscape, unmet needs, current ... TS-1 is an anti-cancer drug which is typically used ... is also used for treating gastric cancer and pancreatic ... potassium. The drug was first approved in 1999 in ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... 25, 2014 Recently, BellasDress ... all its wedding dresses. BellasDress has chosen their best-selling ... gift choices for the holiday season. , Now, ... suitable wedding gowns here at discount prices. The business ... at its website. , “All our elegant ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... at Ohio State University Comprehensive Cancer Center – Arthur ... Institute, have found a tumor suppressor gene that could ... and neck cancers as well as lung cancer. //Their ... up the development of the aforementioned cancers. ,The ...
... functions and converts raw data into meaningful ones? But ... Institute reveals the detailed process in the journal Neuron. ... center is activated and tries to fit everything together ... form of an image, which the person observes and ...
... revealed that early stroke and dementia maybe due to hypertension between ... pressure at an early age should not be ignored. // The ... flow to it due to hypertension, thus raising the chances of ... has been confirmed in as many as 33% of the cases ...
... be more vindictive than women when it comes to taking ... men are more bent upon revenge. The results of the ... researchers conducted the study, which proves that the sex of ... seeking revenge. ,Volunteers who were offended were ...
... who give birth naturally may be better than those who ... both prospective mothers and healthcare// professionals to think again. This ... lesser problems to mothers. ,Some women believe ... life after they have their baby. But the researchers say ...
... in a higher risk of cardiovascular disease or diabetes can ... research conducted by Nadine Sahyoun of the University of Maryland. ... of the study. The study has revealed that elders who ... lower prevalence of metabolic syndrome than people who ate less ...
Cached Medicine News:Health News:Unusual Tumor-Suppressor Gene Switches Off in Lung Cancer 2Health News:Understanding “The Brain 2
The MULTI-LINK ZETA Coronary Stent System utilizes the same clinically proven implant as the MULTI-LINK PENTA Coronary Stent System, maintaining the benefits of a 17.5% binary restenosis rate....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
Medicine Products: